viewCellmid Limited

Cellmid’s évolis Professional product range to be sold in Europe

The évolis® professional products can now be imported into EU countries and the UK following comprehensive safety and compliance reviews.

The evolis professional product range will be sold in the EU by Cellmid’s cosmetics retail partner

Cellmid Limited’s (ASX:CDY) évolis® Professional anti-ageing hair care products have been registered for sale in the European Union and the UK representing the final step in a comprehensive regulatory compliance assessment of the products before they could be freely sold in Europe.

Key treatment and efficacy claims have been retained on the product labels during the review process, which provides for strong market positioning as efficacious products derived from natural plant extracts.

Cellmid has already established a partnership with one of the largest cosmetics retailers in Europe and it is expected that e-commerce sales on the partner’s platform will begin in the first half of financial year 2020.

READ: Cellmid alopecia patent granted in Europe for evolis hair therapy

According to industry reports, 50% of the UK beauty consumers look for products made with natural ingredients and 24% of German consumers choose to buy natural products.

In a discerning market such as the EU, the évolis Professional products - based on plant extracts and with strong clinical evidence - are expected to be well positioned.


The évolis Professional product range of all 11 SKUs will be sold in EU member states by Cellmid’s cosmetics retailer partner.

Sales through the e-commerce platform of Cellmid’s retail partner are expected to begin in the first half of next year in the EU, a large, discerning cosmetics market with relatively high disposable income, similar to the US.

Consistent with the company’s strategic plan released to the market at the end of February, the EU product registration represents yet another important milestone in the company’s plans for the global expansion of the évolis® brand.


Quick facts: Cellmid Limited

Price: 0.105 AUD

Market: ASX
Market Cap: $13.2 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Cellmid Limited named herein, including the promotion by the Company of Cellmid Limited in any Content on the Site, the Company receives from...


Cellmid Limited to supply rapid diagnostic tests to help in new pandemic

Cellmid Limited (ASX:CDY) CEO Maria Halasz tells Proactive's Andrew Scott they've signed an agreement to supply rapid diagnostic tests (RDT), with products expected to arrive in the country by early April. The test uses a virus-specific detection method that delivers results anywhere between...

on 30/3/20

2 min read